A Phase 2 interventional study of Abatacept and Normal Saline in Nephrotic Syndrome, Focal Segmental Glomerulosclerosis and Minimal Change Disease, sponsored by Bristol-Myers Squibb. Completed at 27 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2021-03-05.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Nephrotic Syndrome with a site in United States — 12 open to participants now, 13 under way, none of them phase 3. Nephrotic Syndrome · United States.
Among the 51 studies in Nephrotic Syndrome with a site in United States, this one is the 12th largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2016, is one of 18 in phase 2, and was the 29th registered.
192 studies on the registry are indexed under Nephrotic Syndrome; 65 are open to participants now.
Browse Nephrotic Syndrome studies →12 of the 51 studies in Nephrotic Syndrome with a site in United States are open now. Recruiting first, the newest first:
Vera Therapeutics, Inc. · Sites in United States
Ages 2+
University of California, San Francisco · Sites in United States
Healthy volunteers
University of California, San Francisco · Sites in United States
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 1–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Nephrotic Syndrome studies recruiting now, 23 (46%) set no upper age limit and 22 (44%) stop at 75 or younger; 37 take children under 18; 4 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 19 · Phase 3 5 · Phase 4 5
First in 1986; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 46 across 122 interventional studies indexed under Nephrotic Syndrome.
Median enrollment 26 across the 38 interventional studies, 168 across the 12 observational. Of the 36 that completed or were terminated, 13 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 51 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 1 study filed under Nephrotic Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Nephrotic Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04885179University of California, San FranciscoSPL Insufficiency Syndrome (SPLIS)/NPHS14: a SPLIS Observational Study and Patient Registry (International) | 2026-12-30 |
| NCT06983028Vera Therapeutics, Inc.Atacicept in Multiple Glomerular Diseases | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 51 studies in Nephrotic Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). Candidates must have a prior kidney biopsy with either diagnosis. Another kidney biopsy will not be required as part of the study. Candidates must have failed or be intolerant of prior therapy for their kidney disease. The failed or intolerant therapy must include corticosteroids and at least one other drug. Candidates can be adults and children over the age of 6. Abatacept will be administered by venous infusion every 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Double Blind Periods 1 and 2 (DB1 and DB2): Abatacept IV administered on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period. * Open Label Period (OLE): Abatacept IV administered every 28 days
Drug: Abatacept
* Double Blind Periods 1 and 2 (DB1 and DB2): Normal Saline or Dextrose 5% in Water (D5W) administer on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period. * Open Label Period (OLE): Abatacept IV administered every 28 days
Other: Normal Saline · Other: D5W
Abatacept IV administered on Day 1, 15, 29 and then every 28 days
Normal Saline administer on Day 1, 15, 29 and then every 28 days
Dextrose 5% in Water (D5W) administered on Day 1, 15, 29 and then every 28 days
Also known as: 5% Dextrose in Water
Percentage of Participants in Renal Response at Day 113
Renal Response is defined as the presence of all the following criteria: PROTEINURIA: Reduction of baseline urine protein/creatinine ratio (UPCR) of \>= 50% and to less than 3. RENAL FUNCTION: No worsening of baseline estimated glomerular filtration rate (eGFR) defined as within normal range if normal at baseline or ≥ 75% baseline value if below normal at baseline.
Time frame: From first dose to 113 days following first dose of the indicated period (113 days for Double-Blind Period, 226 days for Open Label Period)
Mean Change From Baseline in Urine Protein/Creatinine Ratio (UPCR) at Day 113
Time frame: From baseline (measured at day 1 of study) to 113 days following first dose administered in the indicated treatment period (113 days for Double-Blind Period, 226 days for Open Label Period)
Mean Change From Baseline in Serum Albumine at Day 113
Time frame: From baseline (measured at day 1 of the study) to 113 days following first dose administered in the indicated treatment period (113 days for Double-Blind Period, 226 days for Open Label Period)
Percentage of Participants Achieving Complete Remission at Day 113
Complete Remission is defined as the presence of all the following criteria: PROTEINURIA: Urine protein/creatinine ratio (UPCR) ≤ 0.3. RENAL FUNCTION: No worsening of baseline estimated glomerular filtration rate (eGFR) defined as within normal range if normal at baseline or ≥ 75% baseline value if below normal at baseline.
Time frame: From first dose to 113 days following first dose of the indicated period (113 days for Double-Blind Period, 226 days for Open Label Period)
Mean Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) at Day 113 - Adult Participants
PROMIS was used to capture patient reported outcomes relevant to participants with nephrotic syndrome. Mean change from baseline is reported for the following measurements: Fatigue: Short From (SF) Fatigue v1.0 Adult 8a, composed of 8 questions, each one scored from 1 (Not at all) to 5 (Very much). Output presented as Total score, ranging from 8 (most desirable outcome) to 40 (least desirable outcome). Pain Interference: SF Pain Interference v1.0 Adult 8a, (measuring how much pain is interfering with daily activities). Composed of 8 questions, each one scored from 1 (Not at all) to 5 (Very much). Output presented as Total score, ranging from 8 (most desirable outcome) to 40 (least desirable outcome). Physical Function: SF Physical Function v1.2 Adult 8b, composed of 8 questions, each one scored from 1 (Without any difficulty) to 5 (Unable to do). Output presented as Total score, ranging from 8 (most desirable outcome) to 40 (least desirable outcome).
Time frame: From baseline (measured at day 1 of study) to 113 days following first dose administered in the Double-Blind Period
Mean Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) at Day 113 - Pediatric Participants
PROMIS was used to capture patient reported outcomes relevant to participants with nephrotic syndrome. Mean change from baseline is reported for the following measurements: Fatigue: Short From (SF) Fatigue v1.0 Peds 10a, composed of 10 questions, each one scored from 0 (Never) to 4 (Almost Always). Output presented as Total score, ranging from 0 (most desirable outcome) to 40 (least desirable outcome). Pain Interference: SF Pain Interference v1.0 Peds 8a, ( measuring how much pain is interfering with daily activities). Composed of 8 questions, each one scored from 0 (Never) to 4 (Almost always). Output presented as Total score, ranging from 0 (most desirable outcome) to 32 (least desirable outcome). Mobility: SF Physical Function-Mobility v1.0 Peds 8a, composed of 8 questions, each one scored from 0 (Not able to do) to 4 (With no trouble). Output presented as Total score, ranging from 0 (least desirable outcome) to 32 (most desirable outcome).
Time frame: From baseline (measured at day 1 of study) to 113 days following first dose administered in the Double-Blind Period
Number of Participants Experiencing Adverse Events
This outcome describes the number of participants experiencing various types of any grade Adverse Events (AEs). The Cumulative Abatacept Safety Period starts at the time of the first dose of Abatacept (either in the Double-Blind Period or in the Open Label Period) and lasts 56 days after the last dose of Abatacept
Time frame: From first dose in the indicated period to 56 days following last dose in the indicated period (169 days for the Double-Blind Period, up to 337 days for the Cumulative Abatacept Safety Period)
Number of Participants Experiencing Adverse Events of Special Interest
Number of participants experiencing various types of Adverse Events of interest, including infections, malignancies, autoimmune disorders, and infusional related reactions.
Time frame: From first dose on day 1 to 56 days following last dose (approximately 330 days)
Percentage of Participants With Positive Antibody Response Relative to Baseline
A positive response relative to baseline is defined as a positive response at a post-baseline visit that has a titer value greater than the positive baseline titer value. If the baseline titer is missing or negative, any post-baseline positive titer value is considered a positive response relative to baseline. Immunogenicity response is presented as the total of immunogenicity response for "CTLA4 and possibly Ig" and "Ig and/or Junction Region".
Time frame: From baseline (day 1) to 168 days following last dose (up to 15 months). Results at day 113 from first dose, day 56, day 84 and day 168 after last dose are presented
Minimum Blood Plasma Concentration (Cmin) of Abatacept - Adult Participants
Time frame: From first dose to 113 days after first dose in the Double Blind Period. Data collected on day 15, day 29, day 57, day 85 and day 113
Minimum Blood Plasma Concentration (Cmin) of Abatacept - Pediatric Participants
Time frame: From first dose to 113 days after first dose in the Double Blind Period. Data collected on day 15, day 29, day 57, day 85 and day 113
Maximum Observed Serum Concentration (Cmax) of Abatacept
Time frame: Day 85 after first dose in the Double Blind Period
Area Under the Serum Concentration Time Curve Over a Dosing Interval (AUC(TAU)) of Abatacept
Time frame: From Day 85 to Day 113 in the Double Blind Period
Time to Reach Peak Serum Concentration (Tmax(h)) of Abatacept
Time frame: Day 85 after first dose in the Double Blind Period
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 17 | 19 |
| Completed | 14 | 13 |
| Not completed | 3 | 6 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: No longer meeting study criteria | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 3 |
| Withdrew: Adverse event | 1 | 2 |
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 14 | 13 |
| Completed | 11 | 11 |
| Not completed | 3 | 2 |
| Withdrew: Skipped db2 and moved into subsequent ole | 3 | 2 |
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 11 | 11 |
| Completed | 6 | 9 |
| Not completed | 5 | 2 |
| Withdrew: Other reasons | 1 | 0 |
| Withdrew: Participant request to discontinue | 1 | 0 |
| Withdrew: No longer meeting study criteria | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 6 | 9 |
| Completed | 5 | 9 |
| Not completed | 1 | 0 |
| Withdrew: Other reasons | 1 | 0 |
| Milestone | Abatacept | Placebo |
|---|---|---|
| Started | 10 | 13 |
| Completed | 6 | 4 |
| Not completed | 4 | 9 |
| Withdrew: Other reasons | 0 | 2 |
| Withdrew: Participant request to discontinue | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Lack of efficacy | 3 | 5 |
| Withdrew: Adverse event | 0 | 1 |
Renal Response is defined as the presence of all the following criteria: PROTEINURIA: Reduction of baseline urine protein/creatinine ratio (UPCR) of \>= 50% and to less than 3. RENAL FUNCTION: No worsening of baseline estimated glomerular filtration rate (eGFR) defined as within normal range if normal at baseline or ≥ 75% baseline value if below normal at baseline.
| Percent of Participants | Abatacept | Placebo |
|---|---|---|
| Double-Blind Period Day 113 | 0.0 (0.0 to 24.7) | 7.7 (0.2 to 36.0) |
| Open Label Period Day 113 | 12.5 (0.3 to 52.7) | 33.3 (7.5 to 70.1) |
| mg/mg | Abatacept | Placebo |
|---|---|---|
| Double-Blind Period Day 113 | 0.12 ± 0.5738 | -0.25 ± 0.7914 |
| Open Label Period Day 113 | 1.98 ± 1.1598 | 0.02 ± 1.3049 |
| g/dL | Abatacept | Placebo |
|---|---|---|
| Double-Blind Period Day 113 | 0.08 ± 0.1016 | -0.05 ± 0.0892 |
| Open Label Period Day 113 | 0.21 ± 0.1829 | 0.09 ± 0.2360 |
Complete Remission is defined as the presence of all the following criteria: PROTEINURIA: Urine protein/creatinine ratio (UPCR) ≤ 0.3. RENAL FUNCTION: No worsening of baseline estimated glomerular filtration rate (eGFR) defined as within normal range if normal at baseline or ≥ 75% baseline value if below normal at baseline.
| Percent of Participants | Abatacept | Placebo |
|---|---|---|
| Double-Blind Period Day 113 | 0.0 (0.0 to 24.7) | 0.0 (0.0 to 24.7) |
| Open Label Period Day 113 | 12.5 (0.3 to 52.7) | 11.1 (0.3 to 48.2) |
PROMIS was used to capture patient reported outcomes relevant to participants with nephrotic syndrome. Mean change from baseline is reported for the following measurements: Fatigue: Short From (SF) Fatigue v1.0 Adult 8a, composed of 8 questions, each one scored from 1 (Not at all) to 5 (Very much). Output presented as Total score, ranging from 8 (most desirable outcome) to 40 (least desirable outcome). Pain Interference: SF Pain Interference v1.0 Adult 8a, (measuring how much pain is interfering with daily activities). Composed of 8 questions, each one scored from 1 (Not at all) to 5 (Very much). Output presented as Total score, ranging from 8 (most desirable outcome) to 40 (least desirable outcome). Physical Function: SF Physical Function v1.2 Adult 8b, composed of 8 questions, each one scored from 1 (Without any difficulty) to 5 (Unable to do). Output presented as Total score, ranging from 8 (most desirable outcome) to 40 (least desirable outcome).
| Score on a scale | Abatacept | Placebo |
|---|---|---|
| Fatigue | -5.56 ± 2.2907 | -4.87 ± 2.6125 |
| Pain Interference | -4.88 ± 2.6395 | -1.18 ± 3.9785 |
| Physical Function | 0.78 ± 1.7350 | 1.77 ± 1.9346 |
PROMIS was used to capture patient reported outcomes relevant to participants with nephrotic syndrome. Mean change from baseline is reported for the following measurements: Fatigue: Short From (SF) Fatigue v1.0 Peds 10a, composed of 10 questions, each one scored from 0 (Never) to 4 (Almost Always). Output presented as Total score, ranging from 0 (most desirable outcome) to 40 (least desirable outcome). Pain Interference: SF Pain Interference v1.0 Peds 8a, ( measuring how much pain is interfering with daily activities). Composed of 8 questions, each one scored from 0 (Never) to 4 (Almost always). Output presented as Total score, ranging from 0 (most desirable outcome) to 32 (least desirable outcome). Mobility: SF Physical Function-Mobility v1.0 Peds 8a, composed of 8 questions, each one scored from 0 (Not able to do) to 4 (With no trouble). Output presented as Total score, ranging from 0 (least desirable outcome) to 32 (most desirable outcome).
| Score on a scale | Abatacept | Placebo |
|---|---|---|
| Fatigue | 6.43 ± 6.7142 | -6.02 ± 3.6526 |
| Pain Interference | 5.70 ± 3.9781 | -1.44 ± 1.9180 |
| Mobility | 0.80 ± 3.5007 | 1.68 ± 3.1905 |
This outcome describes the number of participants experiencing various types of any grade Adverse Events (AEs). The Cumulative Abatacept Safety Period starts at the time of the first dose of Abatacept (either in the Double-Blind Period or in the Open Label Period) and lasts 56 days after the last dose of Abatacept
| Participants | Abatacept During Double-Blind Period | Placebo During Double-Blind Period | Abatacept During Cumulative Abatacept Safety Period |
|---|---|---|---|
| Adverse Events (AEs) | 13 | 15 | 26 |
| Serious Adverse Events (SAEs) | 5 | 4 | 10 |
| AEs leading to discontinuation | 1 | 2 | 2 |
| Deaths | 0 | 0 | 0 |
Number of participants experiencing various types of Adverse Events of interest, including infections, malignancies, autoimmune disorders, and infusional related reactions.
| Participants | Abatacept | Placebo |
|---|---|---|
| Peri-infusional Adverse Event (AE) | 6 | 3 |
| AE within 24 hours of Infusion | 8 | 9 |
| Malignancies | 0 | 0 |
| Infections/Infestations | 12 | 10 |
| Autoimmune disorders | 0 | 1 |
A positive response relative to baseline is defined as a positive response at a post-baseline visit that has a titer value greater than the positive baseline titer value. If the baseline titer is missing or negative, any post-baseline positive titer value is considered a positive response relative to baseline. Immunogenicity response is presented as the total of immunogenicity response for "CTLA4 and possibly Ig" and "Ig and/or Junction Region".
| Percent of Participants | Abatacept | Placebo |
|---|---|---|
| Day 113 from first dose | 7.1 | 0.0 |
| Day 56 from last dose | 40.0 | 66.7 |
| Day 84 from last dose | 28.6 | 66.7 |
| Day 168 from last dose | 16.7 | 25.0 |
| ug/mL | Abatacept | Placebo |
|---|---|---|
| Day 15 | 7.613 ± 63.7 | — |
| Day 29 | 12.274 ± 86.7 | — |
| Day 57 | 3.641 ± 66.5 | — |
| Day 85 | 4.101 ± 52.7 | — |
| Day 113 | 2.786 ± 68.2 | — |
| ug/mL | Abatacept | Placebo |
|---|---|---|
| Day 15 | 2.829 ± 116.4 | — |
| Day 29 | 2.588 ± 138.7 | — |
| Day 57 | 0.504 ± 143.2 | — |
| Day 85 | 1.617 ± 123.5 | — |
| Day 113 | 0.990 ± 163.1 | — |
| ug/mL | Abatacept | Placebo |
|---|---|---|
| Adult participants | 200.46 ± 43.9 | — |
| Pediatric participants | 174.65 ± 30.0 | — |
| ug*h/mL | Abatacept | Placebo |
|---|---|---|
| Adult participants | 20394.83 ± 44.3 | — |
| Pediatric participants | 18282.50 ± 41.9 | — |
| Hours | Abatacept | Placebo |
|---|---|---|
| Adult participants | 0.883 ± 0.242 | — |
| Pediatric participants | 0.589 ± 0.285 | — |
Collected over From first dose to 100 days following administration of last dose (approximately 1 year). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept During Double-Blind Period 1 (DB1) | 0/17 (0%) | 5/17 (29.4%) | 13/17 (76.5%) |
| Placebo During Double-Blind Period 1 (DB1) | 0/19 (0%) | 4/19 (21.1%) | 15/19 (78.9%) |
| Abatacept During Double-Blind Period 2 (DB2) | 0/11 (0%) | 0/11 (0%) | 7/11 (63.6%) |
| Placebo During Double-Blind Period 2 (DB2) | 0/11 (0%) | 2/11 (18.2%) | 8/11 (72.7%) |
| Abatacept During Open Label Period (OLE) | 0/23 (0%) | 6/23 (26.1%) | 16/23 (69.6%) |
| Event | Abatacept During Double-Blind Period 1 (DB1) | Placebo During Double-Blind Period 1 (DB1) | Abatacept During Double-Blind Period 2 (DB2) | Placebo During Double-Blind Period 2 (DB2) | Abatacept During Open Label Period (OLE) |
|---|---|---|---|---|---|
| Generalised oedemaGeneral disorders | 2/17 | 0/19 | 0/11 | 0/11 | 1/23 |
| OedemaGeneral disorders | 2/17 | 0/19 | 0/11 | 0/11 | 0/23 |
| Acute kidney injuryRenal and urinary disorders | 0/17 | 2/19 | 0/11 | 1/11 | 1/23 |
| AnaemiaBlood and lymphatic system disorders | 1/17 | 0/19 | 0/11 | 1/11 | 0/23 |
| Thrombotic microangiopathyBlood and lymphatic system disorders | 0/17 | 0/19 | 0/11 | 1/11 | 0/23 |
| Pneumonia respiratory syncytial viralInfections and infestations | 0/17 | 0/19 | 0/11 | 1/11 | 0/23 |
| Renal failureRenal and urinary disorders | 0/17 | 0/19 | 0/11 | 1/11 | 1/23 |
| Blood creatinine increasedInvestigations | 0/17 | 0/19 | 0/11 | 0/11 | 2/23 |
| Chest painGeneral disorders | 1/17 | 0/19 | 0/11 | 0/11 | 0/23 |
| Fluid overloadMetabolism and nutrition disorders | 1/17 | 0/19 | 0/11 | 0/11 | 0/23 |
| Event | Abatacept During Double-Blind Period 1 (DB1) | Placebo During Double-Blind Period 1 (DB1) | Abatacept During Double-Blind Period 2 (DB2) | Placebo During Double-Blind Period 2 (DB2) | Abatacept During Open Label Period (OLE) |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 5/17 | 2/19 | 0/11 | 0/11 | 3/23 |
| HeadacheNervous system disorders | 2/17 | 5/19 | 1/11 | 2/11 | 2/23 |
| DiarrhoeaGastrointestinal disorders | 4/17 | 3/19 | 0/11 | 1/11 | 3/23 |
| OedemaGeneral disorders | 4/17 | 2/19 | 0/11 | 0/11 | 0/23 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/17 | 0/19 | 0/11 | 2/11 | 0/23 |
| DizzinessNervous system disorders | 3/17 | 0/19 | 0/11 | 0/11 | 0/23 |
| NauseaGastrointestinal disorders | 2/17 | 2/19 | 1/11 | 1/11 | 4/23 |
| PyrexiaGeneral disorders | 1/17 | 2/19 | 0/11 | 0/11 | 4/23 |
| Upper respiratory tract infectionInfections and infestations | 0/17 | 1/19 | 1/11 | 1/11 | 4/23 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/17 | 0/19 | 0/11 | 0/11 | 4/23 |
| Age, Continuous(Years) | Abatacept | Placebo | Total |
|---|---|---|---|
| Mean | 22.5 ± 13.21 | 28.7 ± 19.35 | 25.8 ± 16.80 |
| Sex: Female, Male(Participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| Female | 8 | 12 | 20 |
| Male | 9 | 7 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 5 | 7 |
| Not Hispanic or Latino | 15 | 14 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Abatacept | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 3 | 7 |
| White | 13 | 14 | 27 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Jan 2020, 46 months.
Results were first posted in Mar 2021, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept